{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T17:15:20Z","timestamp":1785863720287,"version":"3.56.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T00:00:00Z","timestamp":1651536000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T00:00:00Z","timestamp":1651536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012957","name":"Friedrich-Schiller-Universit\u00e4t Jena","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012957","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Multi-receptor targeting has been proposed as a promising strategy for the development of opioid analgesics with fewer side effects. Cebranopadol and AT-121 are prototypical bifunctional ligands targeting the nociceptin\/orphanin FQ peptide receptor (NOP) and \u00b5-opioid receptor (MOP) that elicit potent analgesia in humans and nonhuman primates, respectively. Cebranopadol was reported to produce typical MOP-related side effects such as respiratory depression and reward, whereas AT-121 appeared to be devoid of these liabilities. However, the molecular basis underlying different side effect profiles in opioid analgesics remains unknown. Here, we examine agonist-induced receptor phosphorylation and G protein signaling profiles of a series of chemically diverse mixed MOP\/NOP agonists, including cebranopadol and AT-121. We found that these compounds produce strikingly different MOP phosphorylation profiles. Cebranopadol, AT-034 and AT-324 stimulated extensive MOP phosphorylation, whereas AT-201 induced selective phosphorylation at S375 only. AT-121, on the other hand, did not promote any detectable MOP phosphorylation. Conversely, none of these compounds was able to elicit strong NOP phosphorylation and low NOP receptor phosphorylation correlated with partial agonism in a GIRK-channel assay. Our results suggest a close correlation between MOP receptor phosphorylation and side effect profile. Thus, bifunctional MOP\/NOP opioid ligands combining low efficacy G protein signaling at both NOP and MOP with no detectable receptor phosphorylation appear to be devoid of side-effects such as respiratory depression, abuse liability or tolerance development, as with AT-121.<\/jats:p>","DOI":"10.1038\/s41598-022-11189-6","type":"journal-article","created":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T12:03:54Z","timestamp":1651579434000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Attenuated G protein signaling and minimal receptor phosphorylation as a biochemical signature of low side-effect opioid analgesics"],"prefix":"10.1038","volume":"12","author":[{"given":"Pooja","family":"Dasgupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anika","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willma E.","family":"Polgar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer K.","family":"Reinscheid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nurulain T.","family":"Zaveri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,3]]},"reference":[{"issue":"5","key":"11189_CR1","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S0301-0082(02)00008-4","volume":"66","author":"BL Kieffer","year":"2002","unstructured":"Kieffer, B. L. & Gaveriaux-Ruff, C. Exploring the opioid system by gene knockout. Prog. Neurobiol. 66(5), 285\u2013306 (2002).","journal-title":"Prog. Neurobiol."},{"issue":"9","key":"11189_CR2","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1038\/npp.2009.33","volume":"34","author":"M-C Ko","year":"2009","unstructured":"Ko, M.-C. et al. Behavioral effects of a synthetic agonist selective for nociceptin\/orphanin FQ peptide receptors in monkeys. Neuropsychopharmacology 34(9), 2088\u20132096 (2009).","journal-title":"Neuropsychopharmacology"},{"issue":"26","key":"11189_CR3","doi-asserted-by":"publisher","first-page":"14854","DOI":"10.1073\/pnas.94.26.14854","volume":"94","author":"F Jenck","year":"1997","unstructured":"Jenck, F. et al. Orphanin FQ acts as an anxiolytic to attenuate behavioral responses to stress. Proc. Natl. Acad. Sci. 94(26), 14854\u201314858 (1997).","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"9","key":"11189_CR4","doi-asserted-by":"publisher","first-page":"4938","DOI":"10.1073\/pnas.090514397","volume":"97","author":"F Jenck","year":"2000","unstructured":"Jenck, F. et al. A synthetic agonist at the orphanin FQ\/nociceptin receptor ORL1: Anxiolytic profile in the rat. Proc. Natl. Acad. Sci. USA 97(9), 4938\u20134943 (2000).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"11189_CR5","doi-asserted-by":"crossref","unstructured":"Byford, A.J., et al. The hypnotic, electroencephalographic, and antinociceptive properties of nonpeptide ORL1 receptor agonists after intravenous injection in rodents. Anesthesia Analgesia. 104(1), 174\u2013179 (2007).","DOI":"10.1213\/01.ane.0000250403.88649.51"},{"issue":"1","key":"11189_CR6","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00408-009-9197-8","volume":"188","author":"A Woodcock","year":"2010","unstructured":"Woodcock, A. et al. The efficacy of a NOP1 agonist (SCH486757) in subacute cough. Lung 188(1), 47\u201352 (2010).","journal-title":"Lung"},{"issue":"14","key":"11189_CR7","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1111\/bph.13809","volume":"175","author":"T Gunther","year":"2018","unstructured":"Gunther, T. et al. Targeting multiple opioid receptors\u2014Improved analgesics with reduced side effects?. Br. J. Pharmacol. 175(14), 2857\u20132868 (2018).","journal-title":"Br. J. Pharmacol."},{"issue":"3","key":"11189_CR8","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1124\/jpet.109.157446","volume":"331","author":"L Toll","year":"2009","unstructured":"Toll, L. et al. Comparison of the antinociceptive and antirewarding profiles of novel bifunctional nociceptin receptor\/mu-opioid receptor ligands: Implications for therapeutic applications. J. Pharmacol. Exp. Ther. 331(3), 954\u2013964 (2009).","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"11189_CR9","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1124\/jpet.111.184663","volume":"339","author":"TV Khroyan","year":"2011","unstructured":"Khroyan, T. V. et al. Differential effects of nociceptin\/orphanin FQ (NOP) receptor agonists in acute versus chronic pain: Studies with bifunctional NOP\/\u03bc receptor agonists in the sciatic nerve ligation chronic pain model in mice. J. Pharmacol. Exp. Ther. 339(2), 687\u2013693 (2011).","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"11189_CR10","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1124\/jpet.112.194308","volume":"343","author":"CM Cremeans","year":"2012","unstructured":"Cremeans, C. M. et al. Roles of \u03bc-opioid receptors and nociceptin\/orphanin FQ peptide receptors in buprenorphine-induced physiological responses in primates. J. Pharmacol. Exp. Ther. 343(1), 72 (2012).","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"6","key":"11189_CR11","doi-asserted-by":"publisher","first-page":"e146","DOI":"10.1016\/j.bja.2018.10.065","volume":"122","author":"N Kiguchi","year":"2019","unstructured":"Kiguchi, N. et al. BU10038 as a safe opioid analgesic with fewer side-effects after systemic and intrathecal administration in primates. Br. J. Anaesth. 122(6), e146\u2013e156 (2019).","journal-title":"Br. J. Anaesth."},{"issue":"37","key":"11189_CR12","doi-asserted-by":"publisher","first-page":"E5511","DOI":"10.1073\/pnas.1605295113","volume":"113","author":"H Ding","year":"2016","unstructured":"Ding, H. et al. A novel orvinol analog, BU08028, as a safe opioid analgesic without abuse liability in primates. Proc. Natl. Acad. Sci. 113(37), E5511 (2016).","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"456","key":"11189_CR13","doi-asserted-by":"publisher","first-page":"eaar3483","DOI":"10.1126\/scitranslmed.aar3483","volume":"10","author":"H Ding","year":"2018","unstructured":"Ding, H. et al. A bifunctional nociceptin and mu opioid receptor agonist is analgesic without opioid side effects in nonhuman primates. Sci. Transl. Med. 10(456), eaar3483 (2018).","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"11189_CR14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jsat.2014.02.003","volume":"47","author":"EJ Lavonas","year":"2014","unstructured":"Lavonas, E. J. et al. Abuse and diversion of buprenorphine sublingual tablets and film. J. Subst. Abuse Treat. 47(1), 27\u201334 (2014).","journal-title":"J. Subst. Abuse Treat."},{"issue":"3","key":"11189_CR15","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1124\/jpet.114.213694","volume":"349","author":"K Linz","year":"2014","unstructured":"Linz, K. et al. Cebranopadol: A novel potent analgesic nociceptin\/orphanin FQ peptide and opioid receptor agonist. J. Pharmacol. Exp. Ther. 349(3), 535\u2013548 (2014).","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"8","key":"11189_CR16","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1111\/papr.12558","volume":"17","author":"TM Tzschentke","year":"2017","unstructured":"Tzschentke, T. M. et al. Antihyperalgesic, antiallodynic, and antinociceptive effects of cebranopadol, a novel potent nociceptin\/orphanin FQ and opioid receptor agonist, after peripheral and central administration in rodent models of neuropathic pain. Pain Pract. 17(8), 1032\u20131041 (2017).","journal-title":"Pain Pract."},{"issue":"3","key":"11189_CR17","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1124\/jpet.117.241042","volume":"362","author":"G de Guglielmo","year":"2017","unstructured":"de Guglielmo, G. et al. Cebranopadol blocks the escalation of cocaine intake and conditioned reinstatement of cocaine seeking in rats. J. Pharmacol. Exp. Ther. 362(3), 378\u2013384 (2017).","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"5","key":"11189_CR18","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1111\/adb.12550","volume":"23","author":"TM Tzschentke","year":"2018","unstructured":"Tzschentke, T. M. et al. Limited potential of cebranopadol to produce opioid-type physical dependence in rodents. Addict. Biol. 23(5), 1010\u20131019 (2018).","journal-title":"Addict. Biol."},{"issue":"2","key":"11189_CR19","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1111\/j.1476-5381.2011.01382.x","volume":"164","author":"C Doll","year":"2011","unstructured":"Doll, C. et al. Agonist-selective patterns of \u00b5-opioid receptor phosphorylation revealed by phosphosite-specific antibodies. Br. J. Pharmacol. 164(2), 298\u2013307 (2011).","journal-title":"Br. J. Pharmacol."},{"issue":"3","key":"11189_CR20","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1124\/mol.112.082875","volume":"83","author":"S Just","year":"2013","unstructured":"Just, S. et al. Differentiation of opioid drug effects by hierarchical multi-site phosphorylation. Mol. Pharmacol. 83(3), 633\u2013639 (2013).","journal-title":"Mol. Pharmacol."},{"issue":"574","key":"11189_CR21","doi-asserted-by":"publisher","first-page":"eaau8072","DOI":"10.1126\/scisignal.aau8072","volume":"12","author":"A Mann","year":"2019","unstructured":"Mann, A. et al. Agonist-selective NOP receptor phosphorylation correlates in vitro and in vivo and reveals differential post-activation signaling by chemically diverse agonists. Sci. Signal. 12(574), eaau8072 (2019).","journal-title":"Sci. Signal."},{"issue":"3","key":"11189_CR22","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1177\/1087057112461376","volume":"18","author":"A Knapman","year":"2013","unstructured":"Knapman, A. et al. A continuous, fluorescence-based assay of \u03bc-opioid receptor activation in AtT-20 cells. J. Biomol. Screen 18(3), 269\u2013276 (2013).","journal-title":"J. Biomol. Screen"},{"key":"11189_CR23","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3389\/fphar.2011.00064","volume":"2","author":"KB Walsh","year":"2011","unstructured":"Walsh, K. B. Targeting GIRK channels for the development of new therapeutic agents. Front. Pharmacol. 2, 64 (2011).","journal-title":"Front. Pharmacol."},{"key":"11189_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173640","volume":"890","author":"P Dasgupta","year":"2021","unstructured":"Dasgupta, P. et al. Rapid assessment of G protein signaling of four opioid receptors using a real-time fluorescence-based membrane potential assay. Eur. J. Pharmacol. 890, 173640 (2021).","journal-title":"Eur. J. Pharmacol."},{"issue":"8","key":"11189_CR25","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1016\/j.bmc.2014.02.047","volume":"22","author":"VB Journigan","year":"2014","unstructured":"Journigan, V. B. et al. Designing bifunctional NOP receptor-mu opioid receptor ligands from NOP-receptor selective scaffolds. Part II. Bioorg. Med. Chem. 22(8), 2508\u20132516 (2014).","journal-title":"Bioorg. Med. Chem."},{"issue":"2","key":"11189_CR26","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1124\/jpet.106.111997","volume":"320","author":"TV Khroyan","year":"2007","unstructured":"Khroyan, T. V. et al. SR 16435 [1-(1-(bicyclo[3.3.1]nonan-9-yl)piperidin-4-yl)indolin-2-one], a novel mixed nociceptin\/orphanin FQ\/mu-opioid receptor partial agonist: Analgesic and rewarding properties in mice. J. Pharmacol. Exp. Ther. 320(2), 934\u2013943 (2007).","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"3","key":"11189_CR27","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1124\/jpet.109.156711","volume":"331","author":"TV Khroyan","year":"2009","unstructured":"Khroyan, T. V. et al. Nociceptin\/orphanin FQ receptor activation attenuates antinociception induced by mixed nociceptin\/orphanin FQ\/mu-opioid receptor agonists. J. Pharmacol. Exp. Ther. 331(3), 946\u2013953 (2009).","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"11189_CR28","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0014-2999(01)01282-1","volume":"428","author":"N Zaveri","year":"2001","unstructured":"Zaveri, N. et al. Characterization of opiates, neuroleptics, and synthetic analogs at ORL1 and opioid receptors. Eur. J. Pharmacol. 428(1), 29\u201336 (2001).","journal-title":"Eur. J. Pharmacol."},{"issue":"2","key":"11189_CR29","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1111\/acer.13575","volume":"42","author":"NT Zaveri","year":"2018","unstructured":"Zaveri, N. T. et al. A novel and selective nociceptin receptor (NOP) agonist (1-(1-((cis)-4-isopropylcyclohexyl)piperidin-4-yl)-1H-indol-2-yl)methanol (AT-312) decreases acquisition of ethanol-induced conditioned place preference in mice. Alcohol. Clin. Exp. Res. 42(2), 461\u2013471 (2018).","journal-title":"Alcohol. Clin. Exp. Res."},{"issue":"23","key":"11189_CR30","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","volume":"22","author":"Y Cheng","year":"1973","unstructured":"Cheng, Y. & Prusoff, W. H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22(23), 3099\u20133108 (1973).","journal-title":"Biochem. Pharmacol."},{"key":"11189_CR31","doi-asserted-by":"crossref","unstructured":"Dasgupta, P., T. G\u0171nther, & S. Schulz. Pharmacological characterization of veldoreotide as a somatostatin receptor 4 agonist. Life (Basel). 11(10), 1075 (2021).","DOI":"10.3390\/life11101075"},{"issue":"1","key":"11189_CR32","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.regpep.2010.09.004","volume":"167","author":"A Lupp","year":"2011","unstructured":"Lupp, A. et al. UMB-3, a novel rabbit monoclonal antibody, for assessing mu-opioid receptor expression in mouse, rat and human formalin-fixed and paraffin-embedded tissues. Regul. Pept. 167(1), 9\u201313 (2011).","journal-title":"Regul. Pept."},{"issue":"33","key":"11189_CR33","doi-asserted-by":"publisher","first-page":"31408","DOI":"10.1074\/jbc.M100305200","volume":"276","author":"T Koch","year":"2001","unstructured":"Koch, T. et al. C-terminal splice variants of the mouse mu-opioid receptor differ in morphine-induced internalization and receptor resensitization. J. Biol. Chem. 276(33), 31408\u201331414 (2001).","journal-title":"J. Biol. Chem."},{"issue":"16","key":"11189_CR34","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1038\/sj.emboj.7600334","volume":"23","author":"S Schulz","year":"2004","unstructured":"Schulz, S. et al. Morphine induces terminal micro-opioid receptor desensitization by sustained phosphorylation of serine-375. EMBO J. 23(16), 3282\u20133289 (2004).","journal-title":"EMBO J."},{"issue":"12","key":"11189_CR35","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.1021\/jm034249d","volume":"47","author":"NT Zaveri","year":"2004","unstructured":"Zaveri, N. T. et al. A novel series of piperidin-4-yl-1,3-dihydroindol-2-ones as agonist and antagonist ligands at the nociceptin receptor. J. Med. Chem. 47(12), 2973\u20132976 (2004).","journal-title":"J. Med. Chem."},{"issue":"1","key":"11189_CR36","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1097\/j.pain.0000000000000363","volume":"157","author":"ER Viscusi","year":"2016","unstructured":"Viscusi, E. R. et al. A randomized, phase 2 study investigating TRV130, a biased ligand of the \u03bc-opioid receptor, for the intravenous treatment of acute pain. Pain 157(1), 264\u2013272 (2016).","journal-title":"Pain"},{"issue":"8","key":"11189_CR37","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s40261-020-00936-0","volume":"40","author":"S Ayad","year":"2020","unstructured":"Ayad, S. et al. Evaluating the incidence of opioid-induced respiratory depression associated with oliceridine and morphine as measured by the frequency and average cumulative duration of dosing interruption in patients treated for acute postoperative pain. Clin. Drug Investig. 40(8), 755\u2013764 (2020).","journal-title":"Clin. Drug Investig."},{"issue":"1\u20133","key":"11189_CR38","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ejphar.2010.07.036","volume":"645","author":"K Rutten","year":"2010","unstructured":"Rutten, K. et al. Effects of the NOP receptor agonist Ro65-6570 on the acquisition of opiate- and psychostimulant-induced conditioned place preference in rats. Eur. J. Pharmacol. 645(1\u20133), 119\u2013126 (2010).","journal-title":"Eur. J. Pharmacol."},{"issue":"2\u20133","key":"11189_CR39","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S0014-2999(03)02081-8","volume":"474","author":"J Kotlinska","year":"2003","unstructured":"Kotlinska, J. et al. Nociceptin inhibits acquisition of amphetamine-induced place preference and sensitization to stereotypy in rats. Eur. J. Pharmacol. 474(2\u20133), 233\u2013239 (2003).","journal-title":"Eur. J. Pharmacol."},{"issue":"2","key":"11189_CR40","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1124\/pr.114.009209","volume":"68","author":"L Toll","year":"2016","unstructured":"Toll, L. et al. Nociceptin\/orphanin FQ receptor structure, signaling, ligands, functions, and interactions with opioid systems. Pharmacol. Rev. 68(2), 419\u2013457 (2016).","journal-title":"Pharmacol. Rev."},{"issue":"3","key":"11189_CR41","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1208\/s12248-021-00589-7","volume":"23","author":"ME Meyer","year":"2021","unstructured":"Meyer, M. E. et al. Structure-based SAR in the design of selective or bifunctional nociceptin (NOP) receptor agonists. AAPS J. 23(3), 68 (2021).","journal-title":"AAPS J."},{"issue":"11","key":"11189_CR42","doi-asserted-by":"publisher","first-page":"3308","DOI":"10.1016\/j.bmcl.2013.03.101","volume":"23","author":"NT Zaveri","year":"2013","unstructured":"Zaveri, N. T. et al. Designing bifunctional NOP receptor-mu opioid receptor ligands from NOP receptor-selective scaffolds. Part I. Bioorg. Med. Chem. Lett. 23(11), 3308\u20133313 (2013).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"11189_CR43","doi-asserted-by":"crossref","unstructured":"Zaveri, N. T.; Yasuda, D.; Journigan, V. B.; Daga, P. D.; Jiang, F.; Olsen, C. Structure-activity relationships of Nociceptin\nReceptor (NOP) Ligands and the Design of Bifunctional NOP\/mu opioid receptor-targeted Ligands. In Research and\nDevelopment of Opioid-Related Analgesics, (Eds.  Ko, M. C.; Husbands, S. M.,) American Chemical Society: 2013; pp 145\u2013160.","DOI":"10.1021\/bk-2013-1131.ch008"},{"issue":"2","key":"11189_CR44","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1124\/jpet.106.111997","volume":"320","author":"TV Khroyan","year":"2007","unstructured":"Khroyan, T. V. et al. SR 16435 [1-(1-(Bicyclo[3.3.1]nonan-9-yl)piperidin-4-yl)indolin-2-one], a novel mixed nociceptin\/orphanin FQ\/\u03bc-opioid receptor partial agonist: Analgesic and rewarding properties in mice. J. Pharmacol. Exp. Therap. 320(2), 934\u2013943 (2007).","journal-title":"J. Pharmacol. Exp. Therap."},{"issue":"1","key":"11189_CR45","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1124\/jpet.113.203984","volume":"346","author":"DD Sukhtankar","year":"2013","unstructured":"Sukhtankar, D. D. et al. Effects of spinally administered bifunctional nociceptin\/orphanin FQ peptide receptor\/\u03bc-opioid receptor ligands in mouse models of neuropathic and inflammatory pain. J. Pharmacol. Exp. Ther. 346(1), 11\u201322 (2013).","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"11189_CR46","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1111\/adb.12513","volume":"23","author":"M Kallupi","year":"2018","unstructured":"Kallupi, M. et al. Buprenorphine requires concomitant activation of NOP and MOP receptors to reduce cocaine consumption. Addict Biol 23(2), 585\u2013595 (2018).","journal-title":"Addict Biol"},{"key":"11189_CR47","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/164_2019_206","volume":"254","author":"TM Tzschentke","year":"2019","unstructured":"Tzschentke, T. M. et al. Cebranopadol: A novel first-in-class potent analgesic acting via NOP and opioid receptors. Handb. Exp. Pharmacol. 254, 367\u2013398 (2019).","journal-title":"Handb. Exp. Pharmacol."},{"key":"11189_CR48","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/164_2019_211","volume-title":"The Nociceptin\/Orphanin FQ Peptide Receptor","author":"N Kiguchi","year":"2019","unstructured":"Kiguchi, N. & Ko, M.-C. Effects of NOP-related ligands in nonhuman primates. In The Nociceptin\/Orphanin FQ Peptide Receptor (eds Ko, M.-C. & Cal\u00f3, G.) 323\u2013343 (Springer International Publishing, 2019)."},{"key":"11189_CR49","doi-asserted-by":"publisher","unstructured":"Kiguchi, N., H. Ding, & M.-C. Ko. Therapeutic potentials of NOP and MOP receptor coactivation for the treatment of pain and opioid abuse. J. Neurosci. Res. 100(1), 191\u2013202 https:\/\/doi.org\/10.1002\/jnr.24624 (2020).","DOI":"10.1002\/jnr.24624"},{"issue":"9","key":"11189_CR50","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1097\/j.pain.0000000000000986","volume":"158","author":"A Christoph","year":"2017","unstructured":"Christoph, A. et al. Cebranopadol, a novel first-in-class analgesic drug candidate: First experience in patients with chronic low back pain in a randomized clinical trial. Pain 158(9), 1813\u20131824 (2017).","journal-title":"Pain"},{"issue":"3","key":"11189_CR51","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.jpainsymman.2019.05.012","volume":"58","author":"ED Koch","year":"2019","unstructured":"Koch, E. D. et al. Cebranopadol, a novel first-in-class analgesic drug candidate: First experience with cancer-related pain for up to 26 weeks. J. Pain Symptom Manage 58(3), 390\u2013399 (2019).","journal-title":"J. Pain Symptom Manage"},{"issue":"3","key":"11189_CR52","doi-asserted-by":"publisher","first-page":"E193","DOI":"10.36076\/ppj.2018.3.E193","volume":"21","author":"A Scholz","year":"2018","unstructured":"Scholz, A. et al. Cebranopadol: A novel, first-in-class, strong analgesic: Results from a randomized phase IIa clinical trial in postoperative acute pain. Pain Physician 21(3), E193-e206 (2018).","journal-title":"Pain Physician"},{"issue":"2","key":"11189_CR53","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0168-0102(02)00094-9","volume":"44","author":"K Ikeda","year":"2002","unstructured":"Ikeda, K. et al. Molecular mechanisms of analgesia induced by opioids and ethanol: Is the GIRK channel one of the keys?. Neurosci. Res. 44(2), 121\u2013131 (2002).","journal-title":"Neurosci. Res."},{"issue":"1","key":"11189_CR54","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1073\/pnas.0136822100","volume":"100","author":"I Mitrovic","year":"2003","unstructured":"Mitrovic, I. et al. Contribution of GIRK2-mediated postsynaptic signaling to opiate and alpha 2-adrenergic analgesia and analgesic sex differences. Proc. Natl. Acad. Sci. USA 100(1), 271\u2013276 (2003).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"11","key":"11189_CR55","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.1523\/JNEUROSCI.5251-03.2004","volume":"24","author":"CL Marker","year":"2004","unstructured":"Marker, C. L., Stoffel, M. & Wickman, K. Spinal G-protein-gated K+ channels formed by GIRK1 and GIRK2 subunits modulate thermal nociception and contribute to morphine analgesia. J. Neurosci. 24(11), 2806\u20132812 (2004).","journal-title":"J. Neurosci."},{"issue":"8","key":"11189_CR56","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.tips.2004.06.006","volume":"25","author":"RJ Lefkowitz","year":"2004","unstructured":"Lefkowitz, R. J. Historical review: A brief history and personal retrospective of seven-transmembrane receptors. Trends Pharmacol. Sci. 25(8), 413\u2013422 (2004).","journal-title":"Trends Pharmacol. Sci."},{"issue":"1","key":"11189_CR57","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1124\/pr.112.005942","volume":"65","author":"JT Williams","year":"2013","unstructured":"Williams, J. T. et al. Regulation of \u03bc-opioid receptors: Desensitization, phosphorylation, internalization, and tolerance. Pharmacol. Rev. 65(1), 223\u2013254 (2013).","journal-title":"Pharmacol. Rev."},{"issue":"1","key":"11189_CR58","doi-asserted-by":"publisher","first-page":"9254","DOI":"10.1038\/s41598-020-66250-z","volume":"10","author":"H Wei","year":"2020","unstructured":"Wei, H. et al. Effects of cebranopadol on cocaine-induced hyperactivity and cocaine pharmacokinetics in rats. Sci. Rep. 10(1), 9254 (2020).","journal-title":"Sci. Rep."},{"issue":"1","key":"11189_CR59","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1097\/JCP.0000000000000995","volume":"39","author":"K G\u00f6hler","year":"2019","unstructured":"G\u00f6hler, K. et al. Assessment of the abuse potential of cebranopadol in nondependent recreational opioid users: A phase 1 randomized controlled study. J. Clin. Psychopharmacol. 39(1), 46\u201356 (2019).","journal-title":"J. Clin. Psychopharmacol."},{"issue":"3","key":"11189_CR60","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1097\/ALN.0000000000003848","volume":"135","author":"H Ding","year":"2021","unstructured":"Ding, H. et al. Functional profile of systemic and intrathecal cebranopadol in nonhuman primates. Anesthesiology 135(3), 482\u2013493 (2021).","journal-title":"Anesthesiology"},{"issue":"625","key":"11189_CR61","doi-asserted-by":"publisher","first-page":"eaaz3140","DOI":"10.1126\/scisignal.aaz3140","volume":"13","author":"A Gillis","year":"2020","unstructured":"Gillis, A. et al. Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists. Sci. Signal. 13(625), eaaz3140 (2020).","journal-title":"Sci. Signal."},{"issue":"18","key":"11189_CR62","doi-asserted-by":"publisher","first-page":"13873","DOI":"10.1021\/acs.jmedchem.1c01273","volume":"64","author":"S Chakraborty","year":"2021","unstructured":"Chakraborty, S. et al. A novel mitragynine analog with low-efficacy mu opioid receptor agonism displays antinociception with attenuated adverse effects. J. Med. Chem. 64(18), 13873\u201313892 (2021).","journal-title":"J. Med. Chem."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-11189-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-11189-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-11189-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T02:16:28Z","timestamp":1669342588000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-11189-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,3]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["11189"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-11189-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,3]]},"assertion":[{"value":"21 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.S. is the founder and scientific advisor of 7TM Antibodies GmbH, Jena, Germany. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7154"}}